Processa Pharmaceuticals, Inc. · NASDAQ:PCSA
Processa Pharmaceuticals — Medinvest Oncology Investor Conference December 2023
16 slides from Processa Pharmaceuticals's conference presentation, Dec 5, 2023
Slide 1: Next Generation Chemotherapy: Improved Treatment for More Patients
@ Processa Pharmaceuticals “y Next Generation Chemotherapy: Improved Treatment for More Patients David Young, Pharm.D., Ph.D. President, Research & Development & George Ng Chief Executive Officer Processa Pharmaceuticals, Inc (NASDAQ: PCSA) Medinvest Oncology Investor Conference December 2023
Slide 2: Forward Looking Statement and Disclosures
Forward Looking Statement and Disclosures @ Procesa Pharmaceutical This presentation includes forward-looking statements based upon our current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predict
Slide 3: About Processa Pharmaceuticals
About Processa Pharmaceuticals @ Processa Prarmaceutcal Developing the Next-Generation Chemotherapies (NGCs) Designed to Improve Survival and Quality of Life for More Cancer Patients * Ade-risked strategy of developing new chemical entities (NCEs) A = = i — rocessa Pharmaceuticals based on improving
Slide 4: Processa Senior Management
Processa Senior Management George Ng Chief Executive Officer ‘Joined Processa 2023 Former Roles: + President, C00, & Director, Cali Biotherapeutics + Partner, PENG Life Science Ventures + Founder and President, Scilex Pharmaceuticals + JD, University of Notre Dame; B.A.S, Dual Degree, University of
Slide 5: Each Next Generation Chemotherapy (NGC): Potential Annual Sales
Each Next Generation Chemotherapy (NGC): PD Processa Pharmaceuticals Potential Annual Sales of > $500M - $1B Present Chemotherapy NGC (Approx % Pts) (Expected %) Patients Experiencing Side Effects That Require Dose 35% - 70% Reduction or Discontinuation Patients Receiving Full Course Prescribed Chem
Slide 6: How Do NGCs Improve the Safety-Efficacy Profile While Treating More Patients?
How Do NGCs Improve the Safety-Efficacy Profile While @ Processa Prarmaceutcal Treating More Patients? > Each NGC Mechanism of Killing Cancer Cells Remains the Same as Existing FDA-Approved Drug > Alter Metabolism/Distribution of FDA-Approved Cancer Drug or Active Molecules Results in More Exposure
Slide 7: Our NGCs Differ from Current Chemotherapy
@ Provessa Pharmaceuticals Our NGCs Differ from Current Chemotherapy Standard of Care Problem Potential Patient Benefits with Our NGCs Capecitabine — High side effect profile resulting in dose reduction, treatment discontinuation, and less response By changing metabolism and distribution of cancer-
Slide 8: Processa's NGC Pipeline
Processa’s NGC Pipeline @ Processa Pharmaceuticals Next Generation Chemotherapies Improving Safety and Efficacy Development Stage Drug Cancer Indications Preclin Phase 1 | Phase2 | Phase3 NDA Next Generation | Hepatocellular, Pancreatic, Capecitabine Colorectal, Breast, Gastric, & | Zirramaeesuneaen
Slide 9: Optimizing NGC Cancer Treatment
@ Provessa Pharmaceuticals Optimizing NGC Cancer Treatment Processa Develops NGCs Using its Regulatory Science Approach and FDA’s Project Optimus Oncology Initiative * Optimal Dosage Regimen (ODR) creates a better balance between side effects and patient response with potentially — Fewer side effect
Slide 10: Project Optimus Example: Next Generation Irinotecan
Project Optimus Example: Next Generation Irinotecan — @ Press Pharmaceuticals Efficacy Maintained at Lower Doses of NGC-Iri Tumor-Bearing Mice Had 200x Higher Drug In When Compared to Irinotecan in SW620 Colorectal Tumor vs Muscle Compared To 15x With eZ Cancer Xenograft Model Irinotecan NGC-Iri Iri
Slide 11: Next Generation Capecitabine (NGC-Cap)
APY E (NGC-CAP) yf PCS6422 and Capecitabine) fepatocellular, Gastric,
Slide 12: NGC-Cap Not the Same Treatment or Drug as FDA-Approved Capecitabine
NGC-Cap Not the Same Treatment or Drug as FDA-Approved Capecitabine Capecitabine (Xeloda®) /~ 10% - 20% to Anabolites ~ 75% - 85% to FBAL Catabolite Cancer-Killing Side Effects (e.g, HFS) & & Side Effects No Anti-Tumor Properties Renally Excreted * Capecitabine (Oral Pro-Drug of 5-FU) and 5-FU Are M
Slide 13: Highlights of NGC-Cap
Side Effects Highlights of NGC-Cap @ rece Parnes NG ap Fewer Catabolites equals fewer catabolite related side effects in Phase 1b trial Side effects related to Anabolites in Phase 1b trial even though dose is 5-10% of the typical Cap dose (more efficient cancer cell exposure to Anabolites) Efficacy
Slide 14: Next Milestones of NGC-Cap
Next Milestones of NGC-Cap Determine Phase 2 Recommended Dose from stone Approx. Date Ongoing Phase 1b Trial Ongaing Phase 2 Trial Preparation (e.g., Writing Protocol, CRO Selection, Site Interviews, Drug Ongoing Manufacturing) Meet with FDA to Define Project Optimus Phase 2 Trial Design Bee 2023 Su
Slide 15: Why Processa Now?
Why Processa Now? @ Provessa Pharmaceuticals * NGCs provide an improved safety and efficacy profile for FDA-approved cancer- killing molecules allowing more patients to benefit from the NGCs Each NGC has the potential of annual sales > $500M-$1B Upcoming Catalysts/Milestones: — PCS6422/NGC-Cap — PCS
Slide 16: Investor & Media Relations
Investor & Media Relations: CORE IR “IR@processapharma.com
Processa Pharmaceuticals — Medinvest Oncology Investor Conference December 2023 on 6ix